Background: Endometrial cancer (EC) is one of the most common and prevalent gynecologic malignancies worldwide. The aim of this study was to identify a novel therapeutic target for endometrioid endometrial cancer. Materials and Methods: Bioinformatic analysis was performed and CDK1 was screen out as one of the hub genes in the pathogenesis of EC. Immunohistochemistry was used to verify the expression of CDK1 in endometrial cancer tissue. Cell viability and colony formation were used to study the effects of CDK1 on the proliferation and colony formation of endometrial cancer cells in vitro. Apoptosis and cell cycle assays were used to elucidate the mechanism of CDK1 affecting cell proliferation. Tumor xenograft transplantation assay was performed to show the effects of CDK1 on the growth of endometrial cancer cells in vivo. Results: CDK1 was over expressed in endometrioid endometrial cancer, and accumulation of cytoplasmic CDK1 was associated with histological grade of EC. CDK1 promoted endometrial cancer cell growth and colony formation in vitro. The inhibition of CDK1 activity induced cell apoptosis and caused G2/M phase arrest of cell cycle in endometrial cancer cells. The inhibition of CDK1 activity also inhibited endometrial cancer growth in xenograft models. Conclusion: CDK1 was involved in the pathogenesis of endometrioid endometrial cancer and provided a novel therapeutic target for endometrioid endometrial cancer.

AimThe study was conducted to illustrate the clinical characteristics and treatment outcomes of patients with persistent cesarean scar pregnancy (PCSP).MethodsDuring a six‐year period, 38 cases of PCSP were diagnosed and treated conservatively to preserve fertility. The clinical presentations, imaging findings and treatment outcomes of these patients were reviewed.ResultsFourteen out of 38 women (37%) presenting with PCSP suffered heavy vaginal bleeding. Gestational age at diagnosis was 73.1 ± 21.7 days. The maximum diameter of the PCSP mass was 3.6 ± 1.6 cm. The presence of a rich vascular pattern in the area of the PCSP mass was detected by ultrasound in 33/38 (87%) patients. Six patients with a PCSP gestational age of 64.2 ± 6.2 days and a mass diameter of 2.5 ± 0.6 cm were successfully treated with medical treatment alone and 32 patients with a gestational age of 74.8 ± 23.1 days and a mass diameter of 3.8 ± 1.6 cm were successfully treated with surgical or combined treatment.ConclusionsPatients with PCSP are diagnosed at advanced gestational age and are more prone to heavy bleeding. Surgery is the main treatment for PCSP. Medical treatment of PCSP has become an attractive alternative, especially for hemodynamically stable patients with a PCSP mass with a maximum diameter of < 3.5 cm.

No abstract

Objective: Endometrioid ovarian carcinoma (EOC) is gynecological malignancy. Prognostic classification of EOC remains challenging, and the role of molecular markers in predicting prognosis is unclear. Cyclin-dependent kinase 1 (CDK1) has been associated with poor prognosis in several malignancies. Here, we investigate the expression of CDK1 in EOC and its relationship with clinicopathological features and prognosis. Methods: We used bioinformatics, reverse transcription-polymerase chain reaction (RT-PCR), and immunohistochemistry to evaluate the expression of CDK1 in EOC. The correlation between CDK1 expression and clinicopathological features was analyzed using the chi-square test. Survival analysis was performed using Kaplan-Meier curves and multivariate Cox analyses. Results: CDK1 was identified as a hub gene associated with EOC using bioinformatics analysis. CDK1 was significantly overexpressed in EOC compared to endometriosis lesions. Positive cytoplasmic CDK1 expression was associated with poor Disease-specific overall survival (HR=4.579, p=0.005) and poor Progression-free survival (HR=4.333, p=0.003). Cytoplasmic CDK1 expression was an independent predictor of Disease-specific overall survival (p = 0.035). Cytoplasmic CDK1 expression and FIGO stage were independent predictors of Progression-free survival (p = 0.013, p = 0.048). Conclusion: Positive cytoplasmic CDK1 expression was associated with advanced FIGO stage and poor prognosis, and was an independent predictor of Disease-specific overall survival and Progression-free survival. Our results suggest that CDK1 expression may be a useful prognostic marker for EOC.